MiR Scientific, LLC is a precision molecular bioscience company that creates and delivers scalable breakthrough technologies for accessible diagnostic, prognostic, monitoring, and companion products and services for large at-risk cancer populations. The company's services mainly focus on developing liquid biopsy urine tests to definitively detect prostate and bladder cancers, offering a technology to distinguish between aggressive and indolent prostate and bladder tumors, enabling patients to have an alternative treatment at a very low cost and also detect prostate and bladder cancers at their early stage. MiR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.